Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Radioimmunotheragnosis in Cancer Research

Guillermo Garaulet
,
Barbara Baez
ORCID logo ,
Guillermo Medrano
,
María Rivas-Sánchez
ORCID logo ,
David Sánchez-Alonso
,
Jorge L. Martinez-Torrecuadrada
* ORCID logo ,
Francisca Mulero
* ORCID logo
Version 1 : Received: 14 June 2024 / Approved: 17 June 2024 / Online: 17 June 2024 (08:53:13 CEST)

A peer-reviewed article of this Preprint also exists.

Garaulet, G.; Báez, B.B.; Medrano, G.; Rivas-Sánchez, M.; Sánchez-Alonso, D.; Martinez-Torrecuadrada, J.L.; Mulero, F. Radioimmunotheragnosis in Cancer Research. Cancers 2024, 16, 2896. Garaulet, G.; Báez, B.B.; Medrano, G.; Rivas-Sánchez, M.; Sánchez-Alonso, D.; Martinez-Torrecuadrada, J.L.; Mulero, F. Radioimmunotheragnosis in Cancer Research. Cancers 2024, 16, 2896.

Abstract

The combination of immunoPET—where an antibody (Ab) is labeled with an isotope for PET imaging—and radioimmunotherapy (RIT), using the same antibody with a therapeutic isotope, offers significant advantages in cancer management. ImmunoPET allows non-invasive imaging of antigen expression, which aids in patient selection for a subsequent radioimmunotherapy. It also facilitates the assessment of tumor response to therapy, allowing for treatment adjustments if necessary. In addition, immunoPET provides critical pharmacokinetic data, including antibody biodistribution and clearance rates, which are essential for dosimetry calculations and treatment protocol optimization. There are still challenges to overcome. Identifying appropriate target antigens that are selectively expressed on cancer cells while minimally expressed on normal tissues remains a major hurdle to reduce off-target toxicity. In addition, it is critical to optimize the pharmacokinetics of radio-labeled antibodies to maximize tumor uptake and minimize normal tissue uptake, particularly in vital organs such as the liver and kidney. This approach offers the potential for targeted and personalized cancer therapy with reduced systemic toxicity by exploiting the specificity of monoclonal antibodies and the cytotoxic effects of radiation. However, further research is needed to address remaining challenges and to optimize these technologies for clinical use.

Keywords

Theragnosis; Oncology; Nuclear Medicine; ImmunoPET; Radioimmunotherapy

Subject

Medicine and Pharmacology, Clinical Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.